Israel · Delayed Price · Currency is ILS · Price in ILA Scinai Immunotherapeutics Statistics
Total Valuation
TLV:BVXV has a market cap or net worth of ILS 4.03 million. The enterprise value is 23.83 million.
| Market Cap | 4.03M |
| Enterprise Value | 23.83M |
Important Dates
The next estimated earnings date is Tuesday, November 24, 2026.
| Earnings Date | Nov 24, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +303.74% |
| Shares Change (QoQ) | +198.64% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 488,726 |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.91 |
| PB Ratio | 0.12 |
| P/TBV Ratio | 0.22 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 5.30 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.56, with a Debt / Equity ratio of 0.31.
| Current Ratio | 1.56 |
| Quick Ratio | 1.22 |
| Debt / Equity | 0.31 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.48 |
| Interest Coverage | -41.54 |
Financial Efficiency
Return on equity (ROE) is -26.53% and return on invested capital (ROIC) is -41.10%.
| Return on Equity (ROE) | -26.53% |
| Return on Assets (ROA) | -36.15% |
| Return on Invested Capital (ROIC) | -41.10% |
| Return on Capital Employed (ROCE) | -56.16% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | 98,443 |
| Profits Per Employee | -172,060 |
| Employee Count | 45 |
| Asset Turnover | 0.10 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +13.07% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +13.07% |
| 50-Day Moving Average | 48.03 |
| 200-Day Moving Average | 63.36 |
| Relative Strength Index (RSI) | 53.18 |
| Average Volume (20 Days) | 1,402,253 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.11 |
Income Statement
In the last 12 months, TLV:BVXV had revenue of ILS 4.43 million and -7.74 million in losses. Loss per share was -14.57.
| Revenue | 4.43M |
| Gross Profit | -11.18M |
| Operating Income | -25.00M |
| Pretax Income | -7.74M |
| Net Income | -7.74M |
| EBITDA | -19.77M |
| EBIT | -25.00M |
| Loss Per Share | -14.57 |
Balance Sheet
The company has 7.91 million in cash and 10.67 million in debt, with a net cash position of -2.76 million.
| Cash & Cash Equivalents | 7.91M |
| Total Debt | 10.67M |
| Net Cash | -2.76M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 34.95M |
| Book Value Per Share | 31.91 |
| Working Capital | 3.74M |
Cash Flow
In the last 12 months, operating cash flow was -21.97 million and capital expenditures -378,346, giving a free cash flow of -22.35 million.
| Operating Cash Flow | -21.97M |
| Capital Expenditures | -378,346 |
| Depreciation & Amortization | 5.31M |
| Net Borrowing | n/a |
| Free Cash Flow | -22.35M |
| FCF Per Share | n/a |
Margins
Gross margin is -252.32%, with operating and profit margins of -564.36% and -174.78%.
| Gross Margin | -252.32% |
| Operating Margin | -564.36% |
| Pretax Margin | -174.78% |
| Profit Margin | -174.78% |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
TLV:BVXV does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -303.74% |
| Shareholder Yield | -303.74% |
| Earnings Yield | -192.09% |
| FCF Yield | -554.54% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
TLV:BVXV has an Altman Z-Score of -11.27 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -11.27 |
| Piotroski F-Score | 3 |